 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...30313233343536373839404142» |
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
New trial: Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients (clinicaltrials.gov) - May 6, 2016
P=N/A, N=500, Enrolling by invitation, Sponsor: Chinese Academy of Medical Sciences
- |||||||||| Verzenio (abemaciclib) / Eli Lilly
New P3 trial, Metastases: MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) - May 5, 2016
P3, N=450, Not yet recruiting, Sponsor: Eli Lilly and Company
- New trial: CardioVOLT: Cardiovascular Outcomes of Low Testosterone (clinicaltrials.gov) - May 2, 2016
P=N/A, N=379, Active, not recruiting, Sponsor: University of Colorado, Denver
- ||| New trial, Real-world evidence, Real-world, Metastases: Treat ER+ight: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy (clinicaltrials.gov) - Apr 28, 2016
P=N/A, N=320, Recruiting, Sponsor: Novartis Pharmaceuticals
- anastrozole / Generic mfg.
Trial completion: Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence (clinicaltrials.gov) - Apr 27, 2016
P4, N=70, Completed, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Recruiting --> Completed
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Apr 22, 2016
P2, N=32, Active, not recruiting, Sponsor: Midwestern Regional Medical Center
Recruiting --> Completed Not yet recruiting --> Active, not recruiting
- |||| anastrozole / Generic mfg., fulvestrant / Generic mfg.
Trial primary completion date, Metastases: FALCON: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (clinicaltrials.gov) - Apr 20, 2016
P3, N=524, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Apr 2016
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date: Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=150, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jan 2016 --> Apr 2016 Trial primary completion date: Sep 2015 --> Sep 2016
- | vistusertib (AZD2014) / AstraZeneca
New P1/2 trial, Combination therapy, IO biomarker, Metastases: Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) (clinicaltrials.gov) - Apr 7, 2016
P1/2, N=72, Not yet recruiting, Sponsor: Centre Leon Berard
- |||| Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Enrollment open, Metastases: CHEOPS: Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. (clinicaltrials.gov) - Apr 6, 2016
P2, N=130, Recruiting, Sponsor: ARCAGY/ GINECO GROUP
Trial primary completion date: Sep 2015 --> Sep 2016 Not yet recruiting --> Recruiting
- |||||||||| Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
New P3 trial, Combination therapy, Metastases: VICTORIANE: A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease (clinicaltrials.gov) - Apr 6, 2016
P3, N=340, Recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
- Ibrance (palbociclib) / Pfizer
Enrollment change, Combination therapy: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - Mar 25, 2016
P2, N=55, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting N=29 --> 55
- MK-2206 / Merck (MSD)
Trial primary completion date, Combination therapy: Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Mar 24, 2016
P2, N=87, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=29 --> 55 Trial primary completion date: Mar 2016 --> Dec 2016
- | everolimus / Generic mfg.
Enrollment change: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Mar 24, 2016
P2, N=38, Recruiting, Sponsor: Emory University
Trial primary completion date: Mar 2016 --> Dec 2016 N=70 --> 38
- | everolimus / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Mar 21, 2016
P2, N=48, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
N=70 --> 38 Recruiting --> Active, not recruiting
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date: Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer (clinicaltrials.gov) - Mar 18, 2016
P1, N=101, Active, not recruiting, Sponsor: Medivation, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Dec 2015
- anastrozole / Generic mfg., fulvestrant / Generic mfg.
Trial completion: Impact of Endogenous E2 on SSI and GH Rebound (clinicaltrials.gov) - Mar 16, 2016
P1, N=62, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Jun 2016 --> Dec 2015 Active, not recruiting --> Completed
- Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 11, 2016
P2, N=56, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Mar 2016 | Trial primary completion date: Dec 2018 --> Sep 2018
- leuprolide acetate for depot suspension / Generic mfg., anastrozole / Generic mfg.
Trial primary completion date: Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading (clinicaltrials.gov) - Mar 10, 2016
P0, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Mar 2016 | Trial primary completion date: Dec 2018 --> Sep 2018 Trial primary completion date: Jun 2017 --> Feb 2016
- Natrecor (nesiritide) / J&J
Trial primary completion date: Testosterone Regulation of the Natriuretic Peptide System (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jun 2017 --> Feb 2016 Trial primary completion date: Feb 2019 --> Feb 2016
- NN1213 / Novo Nordisk
Enrollment change: Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial. (clinicaltrials.gov) - Mar 9, 2016
P2, N=44, Completed, Sponsor: National Institute on Aging (NIA)
Trial primary completion date: Feb 2019 --> Feb 2016 N=75 --> 44
- || Trial primary completion date, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Mar 8, 2016
P2, N=317, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=75 --> 44 Trial primary completion date: Jul 2016 --> Nov 2016
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Biomarker, Enrollment change, Trial primary completion date, Surgery: NCI-2011-02542: Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery (clinicaltrials.gov) - Mar 5, 2016
P2, N=5, Terminated, Sponsor: University of Maryland
Trial primary completion date: Jul 2016 --> Nov 2016 N=41 --> 5 | Trial primary completion date: Feb 2013 --> May 2017
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Trial termination: 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. (clinicaltrials.gov) - Mar 4, 2016
P2, N=2, Terminated, Sponsor: Katherine Tkaczuk
N=41 --> 5 | Trial primary completion date: Feb 2013 --> May 2017 N=60 --> 2 | Recruiting --> Terminated; funding withdrawn by sponsor
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Feb 24, 2016
P2, N=32, Not yet recruiting, Sponsor: Midwestern Regional Medical Center
- ||| Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: BOOSTER: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Feb 17, 2016
P2, N=160, Active, not recruiting, Sponsor: Japan Breast Cancer Research Group
N=60 --> 2 | Recruiting --> Terminated; funding withdrawn by sponsor Recruiting --> Active, not recruiting
- Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, Trial primary completion date: PREDIX LumB: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (clinicaltrials.gov) - Feb 17, 2016
P2, N=200, Recruiting, Sponsor: Thomas Hatschek
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Feb 2015 | Trial primary completion date: Dec 2017 --> Jun 2018
- Ibrance (palbociclib) / Pfizer
Trial primary completion date, Combination therapy: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - Feb 11, 2016
P2, N=29, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Feb 2015 | Trial primary completion date: Dec 2017 --> Jun 2018 Trial primary completion date: Jan 2016 --> Jan 2017
- Avastin (bevacizumab) / Roche
Enrollment open: Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance (clinicaltrials.gov) - Feb 9, 2016
P1, N=281, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2016 --> Jan 2017 Active, not recruiting --> Recruiting
- anastrozole / Generic mfg.
Trial primary completion date: NEO ER 11-05: Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients (clinicaltrials.gov) - Feb 4, 2016
P2, N=20, Completed, Sponsor: Ottawa Hospital Research Institute
Active, not recruiting --> Recruiting Trial primary completion date: Sep 2013 --> Aug 2014
- anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Enrollment closed: Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring (clinicaltrials.gov) - Feb 2, 2016
P1, N=47, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Sep 2013 --> Aug 2014 Recruiting --> Active, not recruiting
- | everolimus / Generic mfg.
Enrollment change, Trial primary completion date: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Jan 27, 2016
P3, N=1900, Recruiting, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting N=3500 --> 1900 | Trial primary completion date: Mar 2016 --> Dec 2022
- || Verzenio (abemaciclib) / Eli Lilly
Enrollment closed: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Jan 26, 2016
P1, N=102, Active, not recruiting, Sponsor: Eli Lilly and Company
N=3500 --> 1900 | Trial primary completion date: Mar 2016 --> Dec 2022 Recruiting --> Active, not recruiting
- anastrozole / Generic mfg.
Trial primary completion date: ANASILPRA: Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=27, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Jul 2016
- Ibrance (palbociclib) / Pfizer
Trial primary completion date, Combination therapy, Monotherapy, Metastases: TREnd: To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy (clinicaltrials.gov) - Jan 17, 2016
P2, N=100, Recruiting, Sponsor: Fondazione Sandro Pitigliani
Trial primary completion date: Jan 2016 --> Jul 2016 Trial primary completion date: Oct 2015 --> Jun 2016
- || Trial primary completion date: A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy (clinicaltrials.gov) - Jan 17, 2016
P2, N=299, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Oct 2015 --> Jun 2016 Trial primary completion date: Sep 2015 --> Sep 2018
- Avastin (bevacizumab) / Roche
Enrollment closed: Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance (clinicaltrials.gov) - Jan 16, 2016
P1, N=281, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2015 --> Sep 2018 Recruiting --> Active, not recruiting
- | Phase classification, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 7, 2016
P4, N=73, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Phase classification: P2 --> P4
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, PD(L)-1 Biomarker, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jan 7, 2016
P2, N=56, Not yet recruiting, Sponsor: City of Hope Medical Center
- goserelin acetate / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Phase classification, Enrollment change: SEAT: Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients (clinicaltrials.gov) - Dec 30, 2015
P2, N=110, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Phase classification: P2 --> P4 Phase classification: P4 --> P2 | N=330 --> 110
- anastrozole / Generic mfg.
Phase classification: Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer (clinicaltrials.gov) - Dec 25, 2015
P1, N=45, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Phase classification: P4 --> P2 | N=330 --> 110 Phase classification: P=N/A --> P1
- MK-2206 / Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer (clinicaltrials.gov) - Dec 21, 2015
P1, N=31, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P1 Trial primary completion date: Oct 2013 --> Jul 2011
- Enrollment open, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Dec 9, 2015
P2, N=59, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Oct 2013 --> Jul 2011 Active, not recruiting --> Recruiting
- anastrozole / Generic mfg.
Trial completion: Anastrozole in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 6, 2015
P2, N=18, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Trial initiation date, Trial primary completion date: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - Dec 3, 2015
P2, N=70, Not yet recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Initiation date: Aug 2015 --> Feb 2016 | Trial primary completion date: Aug 2022 --> Feb 2023
- MK-2206 / Merck (MSD)
Enrollment closed, Combination therapy: Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Nov 21, 2015
P2, N=87, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2015 --> Feb 2016 | Trial primary completion date: Aug 2022 --> Feb 2023 Recruiting --> Active, not recruiting
- |||| anastrozole / Generic mfg., tamoxifen / Generic mfg.
Trial primary completion date: DATA: Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer (clinicaltrials.gov) - Nov 17, 2015
P3, N=1900, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Mar 2016
- | Ibrance (palbociclib) / Pfizer
New P2 trial: PREDIX LumB: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (clinicaltrials.gov) - Nov 14, 2015
P2, N=200, Not yet recruiting, Sponsor: Thomas Hatschek
- ||||| Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
New P2 trial, Metastases: CHEOPS: Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. (clinicaltrials.gov) - Oct 23, 2015
P2, N=130, Not yet recruiting, Sponsor: ARCAGY/ GINECO GROUP
- || anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Trial primary completion date: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - Oct 22, 2015
P2b, N=318, Recruiting, Sponsor: Bayer
Trial primary completion date: Nov 2015 --> Mar 2016 Trial primary completion date: May 2016 --> Sep 2016